HR 5382
To create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices.
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill aims to allow insulin manufacturers to sell directly to consumers without going through pharmacy benefit managers. Currently, many Americans face high costs for insulin due to the way it’s distributed and priced. The bill proposes a federal mechanism to facilitate these direct sales at the manufacturer’s current net prices, potentially lowering consumer costs. It seeks to address concerns about the affordability of insulin.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Jeff Fortenberry
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.